课题基金 / 基金详情

An Exploration of Neurocognitive Contributors to Functional Recovery Following Cognitive Behavioural Therapy and Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

认知行为疗法和静脉注射氯胺酮治疗难治性抑郁症后对功能恢复的神经认知因素的探索：一项随机、咪达唑仑对照临床试验

批准号：

475697

负责人：

Lipsitz Orly

金额：

$7.65万

依托单位：

University of Toronto Scarborough (ON)

依托单位国家：

加拿大

项目类别：

Studentship Programs

财政年份：

2022

资助国家：

加拿大

项目状态：

未结题

起止时间：

2022-11-01 至 2025-11-01

来源：

https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=475697&lang=en

关键词：

Cognition Cognitive Behavioural Therapy Functional Recovery Ketamine Major Depressive Disorder Randomized Clinical Trial Treatment-Resistant Depression

项目摘要

项目成果

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Major depressive disorder (MDD) is a leading cause of disability among young adults and is the largest growing cause of disability claims in Ontario. Functional impairment in MDD is associated with substantial economic and healthcare costs, increased vuln

期刊论文(0)

专著(0)

科研奖励(0)

会议论文